Full Text View
Tabular View
No Study Results Posted
Related Studies
Generic vs. Name-Brand Levothyroxine
This study is currently recruiting participants.
Study NCT00403390   Information provided by Children's Hospital Boston
First Received: November 21, 2006   Last Updated: May 9, 2008   History of Changes

November 21, 2006
May 9, 2008
June 2006
December 2008   (final data collection date for primary outcome measure)
Thyroid Stimulating Hormone Measure [ Time Frame: 3 points over 16 weeks ] [ Designated as safety issue: No ]
Thyroid Stimulating Hormone Measure
Complete list of historical versions of study NCT00403390 on ClinicalTrials.gov Archive Site
 
 
 
Generic vs. Name-Brand Levothyroxine
Generic vs. Name-Brand Levothyroxine: Assessment of Bioequivalence Using TSH as a Marker in Children With Permanent Hypothyroidism

This study compares two different brands of thyroxine (thyroid hormone). Currently, pharmacists may be substituting generic formulations of thyroid hormone without your doctor knowing about this. Although a small difference in thyroid function is not significant in most healthy children, adolescents and adults, in infants and toddlers even a small difference in thyroid function can have important harmful consequences on brain development. The purpose of the present study is to learn whether the difference between brands of thyroid hormone that are currently being substituted is sufficient to cause a difference in thyroid function.

This study is an unblinded, randomized controlled cross-over study, which involves taking 2 different forms of levothyroxine sequentially over a 16 week period. Subjects will have a total of 3 visits over this time period. At the first visit, subjects are randomized to receive either generic (Sandoz) levothyroxine or Synthroid (Abbott) brand of levothyroxine. Blood is drawn for baseline thyroid function studies and other markers which are influenced by thyroid hormone at each visit. The second visit is the cross-over visit, and the final visit is a close-out visit, after which each subject will resume taking their previous formulation of levothyroxine.

Phase III
Interventional
Treatment, Randomized, Open Label, Active Control, Crossover Assignment, Bio-equivalence Study
  • Congenital Hypothyroidism
  • Hypothyroidism
Drug: Levothyroxine versus Levothyroxine
 
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Recruiting
40
March 2009
December 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Age between 3 and 18 years
  • Diagnosis of Congenital Hypothyroidism with initial TSH > 100
  • Ability to understand directions and follow all instructions

Exclusion Criteria:

  • Not on any drug interfering with absorption of levothyroxine
Both
3 Years to 18 Years
Yes
Contact: Jeremi M Carswell, MD 617-355-6168 Jeremi.Carswell@childrens.harvard.edu
United States
 
NCT00403390
Rosalind Brown, MD Clinical Trials Director, Children's Hospital Boston
05-11-146
Children's Hospital Boston
 
Principal Investigator: Rosalind S Brown, MD Children's Hospital Boston
Children's Hospital Boston
May 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP